Xinfeng Chen, Binghe Tan, Haizhou Xing, Xuan Zhao, Yu Ping, Zhen Zhang, Jianmin Huang, Xiujuan Shi, Na Zhang, Boxu Lin, Weijie Cao, Xin Li, Xudong Zhang, Ling Li, Zhongxing Jiang, Mingzhi Zhang, Wei Li, Mingyao Liu, Bing Du, Yi Zhang
BACKGROUND: Although chimeric antigen receptor T (CAR-T) cells have been proven to be an effective way of treating B cell malignancies, a lot of patients could not benefit from it because of failure in CAR-T cell manufacturing, disease progression, and unaffordable price. The study aimed to explore universal CAR-T cell products to extend the clinical accessibility. METHODS: The antitumor activity of CRISPR/Cas9-edited allogeneic anti-CD19 CAR-T (CAR-T19) cells was assessed in vitro, in animal models, and in patients with relapsed/refractory (R/R) acute B cell lymphoblastic leukemia (B-ALL) or diffuse large B cell lymphoma...
January 17, 2024: Cancer Immunology, Immunotherapy: CII